Soligenix (NASDAQ: SNGX) was featured in a recent article highlighting its approach to drug development through platform technology. The article discusses how the company utilizes synthetic hypericin across two distinct dermatologic indications, illustrating the efficiency and risk management advantages of platform-based drug development.
Platform technology in biopharmaceuticals refers to a foundational system that serves as a base for developing multiple products. By leveraging a shared mechanism of action, manufacturing process, or delivery system, companies can reduce redundancy in preclinical work, regulatory documentation, and safety validation. Soligenix exemplifies this strategy with its synthetic hypericin platform, which is being developed for cutaneous T-cell lymphoma (CTCL) under the name HyBryte (SGX301) and for psoriasis as SGX302.
The company recently completed a successful second Phase 3 study for HyBryte in CTCL and is seeking regulatory approvals for potential commercialization worldwide. Soligenix's pipeline also includes dusquetide (SGX942) for oral mucositis in head and neck cancer and SGX945 for Behçet’s disease, both part of its innate defense regulator technology.
In its Public Health Solutions segment, Soligenix is developing vaccines for ricin toxin (RiVax), filoviruses such as Marburg and Ebola, and COVID-19 (CiVax). These programs utilize the company's proprietary ThermoVax heat stabilization platform technology and have received support from government agencies including NIAID, DTRA, and BARDA.
For more details, the full article can be viewed at https://ibn.fm/Sbnv0. Further information about Soligenix is available on its website at www.Soligenix.com.
